CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Teleconsultation either by phone or by computer consultationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug194 Chloroquine diphosphate Wiki 1.00
drug938 care modalities Wiki 1.00

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D013577 Syndrome NIH 0.15
D011014 Pneumonia NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic: Prospective Observational Study

Since the end of February 2020, Covid-19 infection has spread widely in France, particularly in the East region, with on March 25th, 2020, 5,479 infected patients and 407 deceased patients, including 256 in Alsace. Among the hospitalized patients reported in the initial Chinese studies, 48% had co-morbidity, particularly diabetes or cardiovascular disease. Covid-19 infection does not appear to be more common in diabetic patients, but infected diabetics have more severe forms. The prevalence of diabetes is high in Alsace affecting 6.5% of the population against 4.6% in France. Du to health containment measures, asymptomatic diabetic patients can no longer come to the clinic in Hospital for their consultation. However, in the current epidemiological context, maintaining optimal glycemic control is fundamental since some of diabetic patients will have Covid-19 infections. Furthermore, the sedentary lifestyle and snacking linked to the confinement period will contribute to a glycemic imbalance in some patients. Telemedicine, and in particular teleconsultation, which until now has been very uncommon in the management of diabetic patients, represents a very interesting alternative for monitoring these patients and maintaining satisfactory metabolic control during the current period of confinement and Covid-19 epidemic.

NCT04370171 Diabetes Covid-19 Other: care modalities Other: Teleconsultation either by phone or by computer consultation

Primary Outcomes

Description: In the Covid 19 epidemic context, the face-to-face consultation of diabetic patients with the hospital's physician or their diabetologist is / will be replaced by a teleconsultation ( phone or computer consultation) followed at 6 months of a face-to-face consultation. Patients will be monitored in accordance with routine practice. The Teleconsultation (TC) group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist has been replaced by a teleconsultation due to the availability of diabetologists whose activity is focused on the management of Covid-19 negative patients. The Face-to-Face group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist was postponed by 6 months due to the activity of some diabetologists entirely redirected towards the management of Covid-19 positive patients.

Measure: Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.

Time: HbA1C measured at 3 months post-telemedicine consultation group / post-cancellation of the face-to-face consultation group (variation versus basal)

Secondary Outcomes

Measure: HbA1C measured at 6 months post-telemedicine consultation for the TC group / post-cancellation of the face-to-face consultation for the P group.

Time: HbA1C will be measured at visit V2 (6 months after inclusion visit)=through study completion, an average of 6 months

Measure: Total number of patients inaccessible to teleconsultation and number of patients inaccessible by type of associated reason.

Time: Total number of patients inaccessible to teleconsultation will be collected through study completion, an average of 6 months.

Measure: Number of complications: severe hypoglycemia, ketoacidosis, myocardial infarction, stroke, foot ulcer.

Time: Number of complications through study completion, an average of 6 months.

Measure: Results of patient satisfaction questionnaires.

Time: Patients will respond to the questionnaires either at the end of study (6 months after inclusion) or in the month following the teleconsultation.

Measure: Results of doctor satisfaction questionnaires.

Time: Physician will respond to the questionnaires at study completion, 6 months after the inclusion visit.

Measure: Number of patients infected with Covid-19 (positive smear by RT-PCR for SARS-CoV-2 virus).

Time: Number of patients infected with Covid-19 during the study (6 months).

Measure: Number of conventional hospitalizations, in intensive care and deaths.

Time: Number of conventional hospitalizations, in intensive care and deaths during the study (6 months).

No related HPO nodes (Using clinical trials)